An ad airing Super Bowl Sunday features “America’s deadliest epidemic,” obesity, and what can be done about it with the use of “affordable” compounded weight loss drugs.

Controversy surrounded Hims & Hers’ commercial, called ‘Sick of the System’, in the lead up to America’s biggest sporting event.

Zepbound is a subcutaneous injection that needs proper storage and handling during travel. There are ways you can travel with Zepbound to ensure it remains safe and effective to use. Zepbound ...

Zepbound sales keep soaring, even as weight loss drug growth slows An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York, US, on Thursday, March 28, 2024. - Image ...

Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound surged in the fourth quarter despite missing the company’s initial sales expectations. Zepbound sales reached $1.9 billion in ...

In clinical trials, the most common adverse effect of this treatment was injection site reaction (ISR). This can occur in up to 49% of patients and usually presents as erythema, pruritus ...

Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion. The drugmaker ...

Higher volumes of drugs like Mounjaro, Zepbound, Verzenio ... pen and Rybelsus oral tablet for type II diabetes and as Wegovy injection for weight management. On Wednesday, Novo Nordisk reported ...

GLP-1 drugs Mounjaro and Zepbound drive a big revenue increase for the drugmaker Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound ...

The med's obesity counterpart, Zepbound, reeled in $1.9 billion during the quarter. The figure was roughly an eleven-fold jump from its fourth-quarter haul of $175 million in 2023, shortly after ...